IBC Speakers Predict Reimbursement Woes For Personalized Diagnostic Tests
This article was originally published in The Gray Sheet
Executive Summary
Variation in local Medicare coverage policies for Genentech's Herceptin demonstrates the difficulty CMS will face as predictive molecular diagnostic test use becomes more prevalent, according to Covance VP-Health Economics and Outcome Services David Parker